Drug intelligence / Profile preview

MagTaT

Development stage: Preclinical
Lead developer: ChromoLogic
Modality: Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

MagTaT is a preclinical-stage oral nanoparticle therapeutic being developed by ChromoLogic for the treatment of peripheral neuropathy (PN) and chronic pain. The drug candidate utilizes a proprietary nanoparticle delivery system designed to facilitate oral administration for neurological pain indications. As of the current development stage, ChromoLogic has not publicly disclosed the specific molecular target or the active pharmaceutical ingredient contained within the nanoparticle formulation. The program aims to address the need for effective, non-invasive treatments for chronic neuropathic pain conditions.

Beyond the preview

Go deeper on MagTaT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MagTaT.

Explore the full profile